- Home
- MNTK vs URGN Comparison
MNTK vs URGN Comparison
Compare MNTK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- URGN
- Stock Information
- Founded
- MNTK 1980
- URGN 2004
- Country
- MNTK United States
- URGN United States
- Employees
- MNTK N/A
- URGN N/A
- Industry
- MNTK Natural Gas Distribution
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- URGN Health Care
- Exchange
- MNTK Nasdaq
- URGN Nasdaq
- Market Cap
- MNTK 586.4M
- URGN 547.1M
- IPO Year
- MNTK 2021
- URGN 2017
- Fundamental
- Price
- MNTK $3.95
- URGN $11.33
- Analyst Decision
- MNTK Hold
- URGN Strong Buy
- Analyst Count
- MNTK 2
- URGN 5
- Target Price
- MNTK $6.00
- URGN $44.50
- AVG Volume (30 Days)
- MNTK 170.7K
- URGN 351.4K
- Earning Date
- MNTK 11-12-2024
- URGN 11-06-2024
- Dividend Yield
- MNTK N/A
- URGN N/A
- EPS Growth
- MNTK 42.11
- URGN N/A
- EPS
- MNTK 0.16
- URGN N/A
- Revenue
- MNTK $194,849,000.00
- URGN $89,363,000.00
- Revenue This Year
- MNTK $21.28
- URGN $13.39
- Revenue Next Year
- MNTK $31.59
- URGN $45.06
- P/E Ratio
- MNTK $24.39
- URGN N/A
- Revenue Growth
- MNTK 9.63
- URGN 15.64
- 52 Week Low
- MNTK $3.38
- URGN $10.60
- 52 Week High
- MNTK $9.38
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- MNTK 37.86
- URGN 37.97
- Support Level
- MNTK $3.80
- URGN $11.10
- Resistance Level
- MNTK $4.35
- URGN $13.13
- Average True Range (ATR)
- MNTK 0.20
- URGN 0.53
- MACD
- MNTK 0.02
- URGN -0.10
- Stochastic Oscillator
- MNTK 22.86
- URGN 12.15
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.